Lck SH3 domain function is required for T-cell receptor
signals regulating thymocyte development.
 Nonstandard abbreviations: SCID, severe combined immunodeficiency; TREC, T-cell receptor
excision circle; NBS, newborn screening.
ACTengine involves genetically engineering a patient's own T cells to express novel T-cell receptors
which are specific to Immatics' XPRESIDENT targets.
Using T-cell receptors
(TCRs) that are closely associated with the CD3 complex on their surface, [gamma]/[delta] T cells provide instant defense against pathogens in a nonspecific way at those sites.
The companies entered a research collaboration and licensing agreement in January 2014 to develop novel cancer therapies using Immunocore's Immune Mobilizing Monoclonal T-Cell Receptor
Against Cancer (ImmTAC) technology.
The study found that the killer T-cell receptor
utilises an abnormal mode of binding in order to recognise cells producing insulin.
It is thought that this process gives rise to a phenomenon known as T-cell receptor
promiscuity, which could be responsible for harmful effects T-cells can sometimes cause.
In the case patient, a T-cell receptor
[gamma] locus (TCR[gamma]) gene rearrangement assay was the molecular test performed on the intestinal biopsy specimens to test for the presence of a clonal population of T cells.
It has been well established in the scientific literature that at least two signals are required for T-cell activation and that, if only one signal is supplied to T-cells without the ability of the same T-cells to receive a second activation signal, these T-cells undergo "programmed cell death." The AdapT molecular constructs capitalize on this well known principle and "work" by engaging the antigen-specific T-cell receptor
with one of its peptides and, at the same time, block and inhibit the second signal needed for the full activation of these disease causing T-cells.
Reverse transcriptase-polymerase chain reaction can detect tumor markers in malignant cells in the form of specific chromosomal translocations (such as Philadelphia chromosome in chronic myeloid leukemia) and mutations (such as rearrangement of the T-cell receptor
in non-Hodgkin's lymphoma).
Polymerase chain reaction testing showed that he did have a T-cell receptor
gene rearrangement, but his lymphocytes were normal; so there was no evidence of cutaneous T-cell lymphoma.
Riether volunteered in a clinical study of the effects of a T-cell receptor
vaccine on MS, and her symptoms improved.